文献速递冠心病血脂与心血管预防

再灌注时代无心力衰竭的稳定心梗患者长期β受体阻滞剂治疗的效果:丹麦全国队列研究

Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
PubMed 文献 · Eur Heart J · 2021-01-01

该研究基于丹麦全国注册数据,纳入2003-2018年间首次心梗且接受冠脉造影或PCI、出院后服用阿司匹林和他汀的稳定患者,排除既往心梗、β受体阻滞剂使用或存在其他适应症/禁忌症者。随访3个月至3年,调整后分析显示β受体阻滞剂治疗与心血管死亡、再发心梗及复合心血管事件风险无显著差异。

要点

  • 在无心力衰竭的稳定心梗患者中,长期β受体阻滞剂治疗未显著降低3年心血管死亡和再发心梗风险。
  • β受体阻滞剂与复合心血管事件的绝对风险差异为1.2%(95%CI -0.2%至2.7%),无统计学意义。
  • 研究提示再灌注时代,对已接受优化治疗的无心衰心梗患者,常规长期β受体阻滞剂可能无需普遍应用。

核心结论

  • 在无心力衰竭的稳定、优化治疗的心梗患者中,β受体阻滞剂治疗在3年随访期内未显示对心血管预后有长期保护作用。

主要发现

  • β受体阻滞剂治疗与心血管死亡风险差异0.1%(95%CI -0.3%至0.5%)。
  • β受体阻滞剂治疗与再发心梗风险差异0.2%(95%CI -0.7%至1.2%)。
  • β受体阻滞剂治疗与复合心血管事件风险差异1.2%(95%CI -0.2%至2.7%)。

临床怎么用

  • 对于无心力衰竭、已接受血运重建和优化药物治疗的稳定心梗患者,长期β受体阻滞剂治疗可能不应作为常规推荐。
  • 临床决策应个体化,结合患者具体情况评估β受体阻滞剂的获益与风险。

局限性

  • 观察性设计可能存在残余混杂。
  • 研究人群为丹麦全国注册数据,外推性需谨慎。
  • 随访时间仅3年,长期效果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We aimed to investigate the long-term cardio-protective effect associated with beta-blocker (BB) treatment in stable, optimally treated myocardial infarction (MI) patients without heart failure (HF). METHODS AND RESULTS: Using nationwide registries, we included patients with first-time MI undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) during admission and treated with both acetyl-salicylic acid and statins post-discharge between 2003 and 2018. Patients with prior history of MI, prior BB use, or any alternative indication or contraindication for BB treatment were excluded. Follow-up began 3 months following discharge in patients alive, free of cardiovascular (CV) events or procedures. Primary outcomes were CV death, recurrent MI, and a composite outcome of CV events. We used adjusted logistic regression and reported standardized absolute risks and differences (ARD) 3 years after MI. Overall, 30 177 stable, optimally treated MI patients were included (58% acute PCI, 26% sub-acute PCI, 16% CAG without intervention). At baseline, 82% of patients were on BB treatment (median age 61 years, 75% male) and 18% were not (median age 62 years, 68% male). BB treatment was associated with a similar risk of CV death, recurrent MI, and the composite outcome of CV events compared with no BB treatment [ARD (95% confidence intervals)] correspondingly; 0.1% (-0.3% to 0.5%), 0.2% (-0.7% to 1.2%), and 1.2% (-0.2% to 2.7%). CONCLUSIONS: In this nationwide cohort study of stable, optimally treated MI patients without HF, we found no long-term effect of BB treatment on CV prognosis following the patients from 3 months to 3 years after MI admission.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Holt A, Blanche P, Zareini B, et al. Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. Eur Heart J. 2021. PMID: 33428707. doi:10.1093/eurheartj/ehaa1058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。